Abstracts submissions for AMP Europe 2021 Virtual has been closed.

Submission categories

  • Genetics
  • Genomics and Renal Diseases
  • Hematopathology
  • Infectious Diseases
  • Informatics
  • Molecular Pathology of Metabolic diseases
  • Molecular Cardiovascular Pathology
  • Neurodegenerative diseases, Aging, Oxidative Stress
  • Solid Tumors
  • Technical Topics
  • Other (Education, etc.)*

*Abstract submissions in the “Other (Education, etc.)” topic category may include descriptions of novel educational approaches, innovative programs, pioneering technologies, etc. As with other abstract submissions, these abstract submissions must demonstrate the scientific method, i.e., describe the methodology and data collection, identify how to measure, analyze, and report outcomes, and provide conclusions. All submitted abstracts will be reviewed with the same.

Submission Guidelines

Please type your Abstract Title in title case, e.g., “This Is an Example of Title Case”. You may include italics (gene names), Greek letters, and special symbols, e.g. °C (degree sign), etc. The Abstract Title is limited to no more than 200 characters.

All abstracts are limited to a total of 2,800 characters (including spaces) and either one table or one chart. Your abstract must include the following information:

  1. Introduction: a brief discussion of the background or rationale of the study and/or the question addressed.
  2. Methods: the experimental approach, materials, and methods used in the study.
  3. Results: the data and results obtained in the study.
  4. Conclusions: the conclusions and/or implications of the results.

You must include each of the four section headers in boldface font within the text of your abstract

Abstracts that are not submitted properly will receive an administrative reject and will not be reviewed.

  1. Abstracts must be submitted properly and in English. The online system is a database, with data fields (title, author 1, author 2, author 3, etc.) that are used to generate the published abstracts. Therefore, pay careful attention to the submission instructions and to the submission process, including spelling, capitalization, author names, etc.
  2. All abstracts must include the required headers listed below; each header must be included in your text:
    • Introduction: a brief discussion of the background or rationale of the study and/or the question addressed
    • Methods: the experimental approach, materials, and methods used in the study
    • Results: the data and results obtained in the study
    • Conclusions: the conclusions and/or implications of the results
  3. Abstract Limits:
    • Number of authors: 30
    • Abstract Title: 200 characters
    • Abstract Content: 2800 characters (with spaces and including section headers)
  4. You may include formatting (italicizing genes), Greek letters and special symbols, e.g., °C (degree sign), superscripts, etc. Data must be reported in narrative format in the abstract submission; tables may be included in your poster.
  5. Your abstract will be rated using four criteria:
    • Originality and Clarity
    • Novelty
    • Scientific Merit/Rigor
    • Appropriate Conclusions
  6. Summary: Grounds for abstract rejection are:
    • Failure to follow directions in 1-4.
    • Abstracts that are not eligible for publication in JMD, i.e., have been submitted to another publication or to another meeting that occurs prior to May 2020.
    • Abstract contains no scientific data or has only a promise of future data.
    • Duplicate abstracts are submitted.
    • Any author violated any of the AMP rules for presentation at a previous meeting, e.g., the authors failed to present a poster without notifying AMP prior to the meeting.

The five most common reasons for rejection are:

  • Previously presented/published
  • Poor organization/clarity
  • Does not provide novel information
  • Insufficient scientific quality
  • Insufficient data

Disclosure of Financial Relationships

The AMP Europe 2020 will be an accredited educational activity. To satisfy all requirements, we have implemented a process where everyone who is in a position to influence and/or control the content of an educational activity must disclose all relevant financial relationships with any commercial interest and any conflicts of interest must be resolved prior to the educational activity. Participants of the AMP Europe 2020 must be informed of an organizer’s and/or a presenter’s (speaker, faculty, author, or contributor) academic and professional affiliation and the existence of any relevant financial relationship a presenter has with any proprietary entity producing health care goods or services consumed by, or used on patients, with the exemption of non-profit or government organizations and non-health care related companies. The intent of this disclosure is not to prevent a speaker from making a presentation. This policy allows the listener/attendee to be fully knowledgeable in evaluating the information being presented.

Disclosure includes any relationship that may bias the planning of the educational activity or may bias one’s presentation or which, if known, could give the perception of bias. These situations may include, but are not limited to: 1) stock options or bond holdings in a for-profit corporation or self-directed pension plan; 2) research grants; 3) employment (full or part-time); 4) ownership or partnership; 5) consulting fees or other remuneration; 6) non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson; 7) receipt of royalties; 8) speaker’s bureau; 9) other.

Please note that the Corresponding Author of the abstract must submit an appropriate report of potential competing interests for EACH co-author. For the purposes of submitting an abstract to the AMP Europe 2020, there should be disclosure of any aspect of the author’s personal or professional circumstances (or that of an immediate family members) that could potentially affect the author’s views on the subject that is being presented. The presence of a disclosure of a potential competing interest will not disqualify an abstract for acceptance; however, the disclosure will be noted in the Meeting Program Book, as required by guidelines. The disclosure database is built from these fields. Employees of commercial entities should disclose employment in this section. Noting the Company name in the Author Information field is not sufficient.

Please read the list of circumstances below and evaluate if you (or an immediate family member) have any financial relationship with a commercial concern involving the subject on which you are presenting. For example, financial or reagent support from a company for work reported in the abstract. You must disclose all that apply. You must also disclose the name of the company for any circumstance you disclose. Each time you add an additional author, you will be asked to complete a disclosure report that is specific to that author.


No, so long as each abstract has different content.

No, but if the abstract is accepted, the First Author must register for the AMP Europe Congress and attend the poster.

Corresponding authors will be notified by email by the end of January latest.

YES. The last possible date to withdraw an abstract is March 31, 2020. Notify amp-europe@mci-group.com.

On the left margin of the abstract submitter webpage where it asks, “New User?” click on the “Sign up here” to complete and submit the user registration form.

Email amp@amp.org with your first and last name. Your User Name will be sent to the preferred e-mail address listed on your membership record.

On the left margin of the abstract submitter webpage where it asks, “lost password?” click that link to provide either your Email Address, Customer ID, or User Name to receive an automatic email with your password information.